Recruiting PHASE2 INTERVENTIONAL 2-arm NCT05653193

Interferon-gamma as Adjunctive Therapy in Chronic Pulmonary Aspergillosis: a Randomised Feasibility Study (INCAS)

Sponsor: Manchester University NHS Foundation Trust

Conditions Aspergillosis Chronic Pulmonary Aspergillosis

Interventions Antifungals as standard of care Interferon Gamma-1B 0.1 MG Per 0.5 ML Injection PLUS antifungals as standard of care

Updated 8 times since 2023 Last updated: Feb 27, 2025 Started: May 17, 2024 Primary completion: Nov 30, 2026 Completion: Dec 31, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05653193, this PHASE2 trial focuses on Aspergillosis and Chronic Pulmonary Aspergillosis and remains actively recruiting participants. Sponsored by Manchester University NHS Foundation Trust, it has been updated 8 times since 2024, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Apr 2025 — Present [monthly]

Recruiting PHASE2
Sep 2024 — Apr 2025 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting PHASE2
Nov 2023 — Jul 2024 [monthly]

Not Yet Recruiting PHASE2
Aug 2023 — Nov 2023 [monthly]

Not Yet Recruiting PHASE2

▶ Show 3 earlier versions

May 2023 — Aug 2023 [monthly]

Not Yet Recruiting PHASE2
Mar 2023 — May 2023 [monthly]

Not Yet Recruiting PHASE2
Jan 2023 — Mar 2023 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Manchester University NHS Foundation Trust

Data source: Manchester University NHS Foundation Trust

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Manchester, United Kingdom